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Context: Hyponatremia is the most common electrolyte disorder encountered in clinical practice
and represents a clinical, social, and economic burden. Conventional treatments of hyponatremia
present some pitfalls, such as suboptimal efficacy, risk of overly rapid correction, and adverse
effects. Vasopressin receptor antagonists, known as vaptans, represent a new and interesting class
of drugs for the treatment of the euvolemic and hypervolemic forms of hyponatremia.
Evidence Acquisition: This review is based on a PubMed search with the following terms: “vap-
tans,” “vasopressin receptor antagonists,” “tolvaptan,” “conivaptan,” “vasopressin receptor an-
tagonists and SIADH,” “vasopressin receptor antagonists and congestive heart failure,” “vaso-
pressin receptor antagonists and cirrhosis,” and “vasopressin receptor antagonists and polycystic
kidney disease.”
Evidence Synthesis: Overall, the studies reported in this review indicate that vaptans effectively
correct hyponatremia in euvolemic and hypervolemic patients. In the latter group, vaptans gen-
erally had favorable effects on fluid balance also. To date two vaptans, ie, conivaptan and tolvap-
tan, have been marketed in the United States for the treatment of euvolemic and hypervolemic
hyponatremia, whereas tolvaptan has been marketed in Europe with the limitation of euvolemic
hyponatremia. Although these drugs have a good safety profile, caution should be used, and
treatment should be initiated in a hospital setting in order to closely monitor patients and avoid
overly rapid correction or overcorrection.
Conclusions: Vaptans can be considered a new effective tool for the treatment of euvolemic and
hypervolemic hyponatremia. Nevertheless, more comparative research of vaptans vs other ther-
apies on clinical grounds is needed to more accurately assess the value of these drugs in the
treatment of hyponatremia. (J Clin Endocrinol Metab 98: 0000–0000, 2013)
Hyponatremia is themost common electrolyte disorderencountered in clinical practice.Mildhyponatremia
(serum [Na] between 130 and 135 mmol/L) occurs in
about 20% of hospitalized patients, whereas moderate to
severe hyponatremia (serum [Na]130mmol/L) occurs
in up to 7% of hospitalized patients (1, 2).
Hyponatremia, which is an independent predictor of
in-hospitalmortality (3–5), represents a clinical and social
burden. This is demonstrated by several studies published
in the last few years that showed that mild, chronic hy-
ponatremia may also lead to negative consequences on
health status, such as altered gait and increased fall risk
(6), attention deficits (7), fractures (8), and bone loss (9,
10). More recently, sustained hyponatremia has been
shown to cause multiple manifestations of senescence in a
rat model of the syndrome of inappropriate antidiuretic
hormone (ADH) secretion (SIADH), including cardiomy-
opathy, skeletal muscle sarcopenia, decreased body fat,
andhypogonadism(11).This electrolytedisorderhasbeen
linked to increased healthcare resource consumption and
longer hospital stay, thus causing increased healthcare
costs (12).
Hyponatremia is the consequence of an excess of water
relative to total body sodium and can be associated with
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in U.S.A.
Copyright © 2013 by The Endocrine Society
doi: 10.1210/jc.2012-4082 Received December 3, 2012. Accepted January 15, 2013.
Abbreviations: ADH, antidiuretic hormone; CHF, congestive heart failure; LOS, length of
stay; PKD, polycystic kidney disease; SIAD, syndrome of inappropriate antidiuresis; SIADH,
syndrome of inappropriate ADH secretion; V1 receptor, vasopressin type 1 receptor; V2
receptor, vasopressin type 2 receptor.
S P E C I A L F E A T U R E
C l i n i c a l R e v i e w
J Clin Endocrinol Metab, April 2013, 98(4):0000–0000 jcem.endojournals.org 1
 J Clin Endocrin Metab. First published ahead of print February 11, 2013 as doi:10.1210/jc.2012-4082
Copyright (C) 2013 by The Endocrine Society 
increased, normal, or reduced plasma osmolality. Hypo-
tonic hyponatremia is themost frequent formencountered
in clinical practice and can be classified based on extra-
cellular volume status into hypovolemic, euvolemic, and
hypervolemic forms (13). Patients with hypovolemic hy-
ponatremia are effectively treated with isotonic saline
(0.9% NaCl) infusion. In patients with euvolemic or hy-
pervolemic hyponatremia, conventional therapeutic op-
tions include fluid restriction, hypertonic saline (3%
NaCl) infusion, and loop diuretics (13–15). Hypertonic
saline infusion has been classically considered the treat-
ment of choice in the presence of acute symptomatic hy-
ponatremia. This approach requires great caution because
an overly rapid correction of hyponatremia may cause
brain damage, ultimately leading to the osmotic demyeli-
nation syndrome (13–15). Fluid restriction represents the
safemainstay ofmanagement of asymptomatic euvolemic
or hypervolemic hyponatremia. However, the efficacy of
this approach is negatively affected by the modest im-
provement of serum [Na] and the poor compliance of the
patients because of increased thirst (13, 14). In addition,
fluid restriction will not work in patients who are not
excreting free water (16). Other options for the treatment
of euvolemic or hypervolemic hyponatremia (eg, deme-
clocycline, urea, lithium) are considered suboptimal for
several reasons, including variable efficacy, slow re-
sponses, and serious toxicities (13, 14) (Table 1).
Vaptans represent a new class of drugs developed for
the treatment of euvolemic or hypervolemic hyponatre-
mia. These drugs are nonpeptide vasopressin receptor an-
tagonists and, bybindingvasopressin type2 (V2) receptors
expressed in renal collecting duct cells, cause water diure-
sis, namely aquaresis, thus increasing serum [Na]. This
review will address the development and mechanism of
action of vaptans, clinical trials, and current use in clinical
practice, as well as future perspectives.
The Development of Vasopressin Receptor
Antagonists
The vasopressor and antidiuretic activity of hypophyseal
extracts was first described between the end of the 19th
century and the beginning of the 20th century (17–20).
Only after the isolation and synthesis of vasopressin was
it clear that the same hormone is responsible for both va-
sopressor and antidiuretic effects (21, 22).
The early studies on the effects of neurohypophysial
peptide analogs on water diuresis were performed at Cor-
nell University (New York, New York) by the Nobel
laureate Vincent du Vigneaud, who reported the antiva-
sopressin activity of two analogs of oxytocin, [4-leucine]-
oxytocin and [2,4-diisoleucine]-oxytocin, in rats (23, 24).
In the 1980s, a number of studies reported the identifica-
tion of competitive V2 receptor antagonists, which in-
duced aquaresis in different animal models, such as rats,
dogs, andmonkeys (25). However, none of them emerged
as a useful clinical antidiuretic antagonist because of low
oral bioavailability, species differences, and mostly, ago-
nistic effects when administered to humans (26–29).
A new era for the development of vasopressin receptor
antagonistswas started in 1991,when the first nonpeptide
vasopressin type 1 (V1) receptor antagonist was identified
(30). This compound (OPC-21268) selectively and com-
petitively antagonized the binding to the V1 receptor and
counteracted vasopressin-induced vasoconstriction after
oral administration in rats.One year later, the discoveryof
a nonpeptideV2 receptor antagonist (OPC-31260),which
caused aquaresis in rats, was reported (31). The first suc-
cessful use of a nonpeptide V2 receptor antagonist in hu-
mans was reported in 1993 (32). Several nonpeptide va-
sopressin receptor antagonists were developed in the
following years, including OPC-41061 and YM087,
which subsequently became familiar to clinicians with the
names “tolvaptan” and “conivaptan,” respectively
(33–36).
Mechanism of Action of V2 Receptor
Antagonists
V2 receptor antagonists, collectively known as vaptans,
were thought to be therapeutically useful for the treatment
of diseases characterized by fluid retention. They compet-
itively block the binding of vasopressin to V2 receptors,
which are located on renal collecting duct cells. This pre-
vents vasopressin-mediated activation of these receptors.
As a consequence of receptor inactivation, the synthesis
and transport of aquaporin-2 water channel proteins into
the apicalmembraneof the collectingduct cells is inhibited
(13, 37) (Figure 1). This prevents free water reabsorption
Table 1. Advantages and Problems of Conventional
Treatments for Hypotonic Euvolemic or Hypervolemic
Hyponatremia
Therapy Advantages Problems
Fluid restriction Inexpensive Modest efficacy, poor
compliance
Hypertonic saline Effective Possible overly rapid
correction
Loop diuretics Effective in
correcting volume
overload
Electrolyte imbalance
Demeclocycline Generally effective Slow onset of action,
nephrotoxicity
Lithium Sometimes effective Inconsistent efficacy,
adverse effects
Urea Generally effective Unpleasant taste,
limited experience
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and causes increased urine volume. Noteworthy, the in-
creased diuresis produced by V2 receptor antagonists is
quantitatively similar to diuretics such as furosemide, but
it is qualitatively different because there is not a significant
increase in the excretion of urine solutes, such as sodium
and potassium. Therefore, V2 receptor antagonists pro-
duce aquaresis, which is characterized by a decrease in
urine osmolality and an increase in serum [Na]. The
aquaretic effect is therefore the hallmark of these com-
pounds and distinguishes them from traditional diuretics.
Vaptans: Clinical Trials
Several vaptans have been developed and tested in hu-
mans. Besides tolvaptan and conivaptan, this list includes
lixivaptan, mozavaptan, satavaptan, and RWJ351647
(38) (Figure 2). These molecules bind V2 receptors with
a relative specificity, with the exception of conivaptan,
which shows affinity for both V1a and V2 receptors. All
vaptans can be administered orally, but conivaptan can
also be administered iv. The pharmacological proper-
ties of the most investigated vaptans are shown in Table
2. Because of their mechanism of action, vaptans are not
to be used in hypovolemic hyponatremia, whereas pos-
itive effects on fluid balance and on natremia can be
predicted in patients with euvolemic or hypervolemic
hyponatremia.
Vaptans in euvolemic hyponatremia
Patients with euvolemic hyponatremia were included
with patients with hypervolemic hyponatremia in several
clinical trials of treatment with vaptans, and the results
were pooled together in most cases.
In two placebo-controlled, randomized, double-blind
studies, 74 and 83 patients, respectively, with euvolemic
or hypervolemic hyponatremia received oral conivaptan
or placebo for 5 days (39, 40). In both trials, conivaptan
(40 or 80 mg/d) caused a significantly greater increase in
the area under the curve for serum [Na] from baseline
than placebo. In addition, patients treated with conivap-
tan had a faster and more prolonged increase of serum
[Na] compared to patients treated with placebo.
Conivaptan was generally well tolerated; headache, hy-
potension, nausea, postural hypotension, urinary tract in-
fections, pyrexia, and hypokalemia were among the most
frequent adverse events. Similar results were obtained
Vaptans block the binding              Synthesis and transport of AQP-2         This prevents free
of AVP to the V2 receptors              proteins is reduced                                  water absorption
Figure 1. Schematic representation of the mechanism of action of vaptans. [Reproduced from A. Peri et al.: Hyponatremia and the syndrome of
inappropriate secretion of antidiuretic hormone (SIADH). J Endocrinol Invest. 33:671–682, 2010 (14), with permission. © Editrice Kurtis.]. AVP,
arginine vasopressin; AQP-2, aquaporin-2.
Figure 2. Chemical structure of the most investigated vaptans.
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with iv administration of conivaptan (41) and with oral
lixivaptan (42). Two multicenter, randomized, double-
blind, placebo-controlled trials, the Study of Ascending
Levels of Sodium in Hyponatremia 1 and 2 (SALT-1 and
SALT-2), evaluated the efficacy of tolvaptan in patients
with euvolemic or hypervolemic hyponatremia (43). Pa-
tients were randomly assigned to receive oral tolvaptan
(n225; 15–60mg/d) or placebo (n223). Serum [Na]
increased to a greater extent in the tolvaptan group than
in the placebo group during the first 4 days and at the
completion of the treatment period (30 d). This difference
was also maintained when patients were stratified into
subgroups according to whether hyponatremia was de-
fined as mild (130–135 mmol/L) or marked (130
mmol/L) at baseline. Hyponatremia recurred soon after
discontinuation of tolvaptan. Commonly observed side
effects included increased thirst and dry mouth, in agree-
ment with the aquaretic effect of the drug. In only 4 pa-
tients in the tolvaptan group, serum [Na] correction ex-
ceeded the desirable rate of 0.5 mmol/Lh during the first
24 h of the study, and in only 4 patients serum [Na]
increased beyond 146 mmol/L. Interestingly, a combined
analysis of the two trials showed a significant increase in
the score of the mental component of the SF-12 health
survey frombaseline to day 30 in the tolvaptan group. The
subsequent SALTWATER trial was a multicenter, open-
label extension of the SALT-1 and SALT-2 trials (44). A
total of 111 hyponatremic patients received tolvaptan for
a mean follow-up of almost 2 years. Serum [Na] nor-
malization occurred rapidly andwasmaintained through-
out the observation period. Patients with euvolemic hy-
ponatremia and those with congestive heart failure (CHF)
showed similar responses, whereas the efficacy of tolvap-
tanappeared less evident inpatientswith cirrhosis. Similar
to the results of the SALT-1 and SALT-2 trials, an exces-
sive rate of serum [Na] increase or hypernatremia was
also rarely observed in the SALTWATER trial. Another
interesting study evaluated the effect of tolvaptan (10–60
mg/d) vs fluid restriction (1200 ml/d) on serum [Na] in
hospitalized patients with euvolemic (36%) or hypervo-
lemic (64%) hyponatremia (45). At the last inpatient visit
(about 2 wk after the initiation of treatment), the mean
increase in serum [Na] was close to 6 mmol/L in the
tolvaptan group and 1 mmol/L in the fluid restriction
group, whereas no difference in adverse events was
observed.
Other clinical studies exclusively addressed the effect of
vaptans in patients with euvolemic hyponatremia and
therefore included only patients with SIADH. This syn-
drome has been recently referred to alsowith the acronym
SIAD, for syndrome of inappropriate antidiuresis. The
new terminology has been proposed after the first descrip-
tion of infants with clinical and laboratory features con-
sistent with the presence of SIADH, but with undetectable
ADH levels. Gain-of-function mutations in the V2 recep-
tor gene were identified in these patients (46). The new
term SIAD also includes this type of patients, and in the
opinion of the author of this review it should be preferred
to the traditional acronym SIADH, although there has
been no formal renaming of the syndrome so far.
The effects of oral satavaptan in patients with SIAD
were evaluated in 34 patients enrolled in a randomized,
double-blind study. Both 25 and 50 mg/d of satavaptan
caused a greater increase in serum [Na] (mean basal con-
centration was 127 mmol/L) than placebo starting from
day 2.Mean serum [Na] continued to rise gradually, and
the persistent effect of satavaptan was also evident in an
open-label follow-up treatment for up to 12 months (47).
In another study, 56 patients with hyponatremia (serum
[Na] from 115 to 129 mmol/L) due to SIAD received
conivaptan (40 or 80 mg/d via continuous iv infusion) or
placebo for 4 days. Both doses of the drug significantly
increased serum [Na] more than placebo after 2 and 4
days of treatment; on day 4, the mean increase from base-
line was 8.4 and 6.1 mmol/L with conivaptan (80 and 40
mg/d, respectively) and 2.8 mmol/L with placebo (48).
Similar results were obtained with mozavaptan, adminis-
tered for 7 days to patients with paraneoplastic SIAD
caused by ectopic ADH secretion (49).
The efficacy of vaptans in correcting hyponatremia as-
sociated with paraneoplastic SIAD was confirmed in 13
hyponatremic patients, 7 ofwhomwere affected by small-
cell lung cancer, treated with tolvaptan. In some patients,
overcorrection occurred (in one case, serum [Na] in-
Table 2. Pharmacological Properties of the Most Investigated Vaptans
Pharmacological Properties Tolvaptan Lixivaptan Satavaptan Conivaptan
Receptor specificity V2 V2 V2 V1a/V2
Route of administration Oral Oral Oral Intravenousa
Elimination half-life, h 6–8 7–10 14–17 3–8
Metabolism Hepatic Hepatic Hepatic Hepatic
Dosage, mg/d 15–60 10–400b 5–50b 20–40
a An oral formulation has been evaluated in clinical studies but is not currently approved for use.
b Doses used in clinical trials.
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creased from 114 to 131mmol/Lwithin 24 h after a single
dose of 15 mg), and the authors hypothesized a higher
sensitivity to tolvaptan in paraneoplastic SIAD (50). A
subgroup analysis of patients with SIAD (n 110) in the
SALT-1 and SALT-2 trials revealed that the change in the
average daily area under the curve for serum [Na] from
baseline to day 4 and from baseline to day 30 was signif-
icantly greater in the tolvaptan group compared to the
placebo group (on d 4, 5.28  3.35 vs 0.47  2.81
mmol/L, respectively; on d 30, 8.07 4.55 vs 1.89 4.13
mmol/L, respectively) (51). The SF-12 Health Survey re-
vealed a significant positive effect of tolvaptan on the
physical component and a near-significant trend on the
mental component in SIAD patients. With regard to
safety, no serious adverse event in patients treated with
tolvaptan was considered to be related to the medication;
similarly, the 1death occurring in the tolvaptan groupwas
not considered treatment-related. Finally, a long-termBel-
gian trial in patients with chronic SIAD compared the ef-
ficacy, tolerability, and safety of vaptans vs urea. Twelve
patients were treated with satavaptan or tolvaptan for 1
year, followed by a 1-year treatment with urea (52). The
conclusions of the studywere that urea has efficacy similar
to vaptans in increasing serum [Na] and it is generally
well tolerated. Human studies have shown the efficacy of
long-term treatment with urea (53). Anyway, it has to be
said that not many centers have experience in the use of
urea, which is not available inmany countries, and that its
unpleasant taste has limited its use. Data regarding trials
with vaptans specifically in patients with SIAD are sum-
marized in Table 3.
Vaptans in hypervolemic hyponatremia: CHF
Several studies specifically addressed the use of vaptans
in patients with CHF (54–61). These studies reported pri-
marily the effects of different vaptans (ie, tolvaptan, lix-
ivaptan, or conivaptan) on hemodynamic parameters,
whereas only a minority of patients had hyponatremia.
Overall, these studies showed that vaptans caused favor-
able changes inhemodynamics andwater balance andalso
serum [Na] increase in patients with CHF. No serious
adverse events were observed as a consequence of the
treatment. Two of these studies also addressed the effects
of tolvaptan on survival. In one study (Acute and Chronic
Therapeutic Impact of a Vasopressin Antagonist in
Chronic Heart Failure [ACTIV in CHF]), patients who
were treated with tolvaptan (30–90 mg) and who had an
increase in serum [Na] of at least 2 mmol/L had half the
mortality rate (11%) 2 months after discharge compared
to patients with no serum [Na] improvement (56). On
the contrary, in the other study (Efficacy of Vasopressin
Antagonism inHeartFailureOutcomeStudywithTolvap-
tan [EVEREST]), treatment with tolvaptan (30 mg/d) for
2 months raised serum [Na] levels and improved some
hemodynamic indexes, but it did not affect mortality or
morbidity compared to placebo (57). However, further
beneficial effects of tolvaptanon signs and symptomswere
confirmed in theEVEREST trial by subsequent post hocor
subset analyses (60, 61). Similarly, the Dilutional Hypona-
tremia(DILIPO)trial,which includedmostlyCHFpatients,
demonstrated the long-term (up to 343 d of treatment)
efficacy of satavaptan on serum [Na] correction and
weight loss (62). However, higher rates of adverse events,
including overly rapid correction of hyponatremia, were
reported in patients treated with satavaptan compared to
placebo.
Other recent studies showed that the use of vaptans
(tolvaptan or conivaptan) as an add-on treatment to con-
ventional diuretics (mostly furosemide) in patients with
CHFwas tolerable and effective in reducing volume over-
load (63–66) and causedagreater increase of serum [Na]
compared to furosemide alone (67). Altogether, these
studies indicate that in patients with CHF and signs of
volume overload despite using conventional diuretics,
vaptans can be a valuable option in order to improve con-
gestive symptoms and signs and spare electrolyte loss.
Vaptans in hypervolemic hyponatremia: cirrhosis
Clinical trials have assessed the efficacy of different
vaptans exclusively in patients, mostly normonatremic,
with liver cirrhosis. The oldest of them demonstrated that
a single oral dose of mozavaptan increased diuresis and
Table 3. Trials with Vaptans That Included Patients with SIAD Exclusively
First Author
(Ref.) Trial Type and Length
Patients
(n) Drug
Dose,
mg/d Route Efficacy
Overcorrection
(n)
Soupart (47) R, DB  OL, PC, 12 months 34 Satavaptan 25–50 Oral Yes 7
Verbalis (48) MC, R, DB, PC, 4 d 56 Conivaptan 40–80 Intravenous Yes 1
Yamaguchi (49) MC, OL, 7 d 16 Mozavaptan 30 Oral Yes None
Kenz (50) OL, up to 4 mo 13 Tolvaptan 7.5–30 Oral Yes 2
Verbalis (51) MC, R, DB, PC, 30 d 110 Tolvaptan 15–60 Oral Yes 3
Soupart (52) OL, 12 mo 10 Satavaptan 5–50 Oral Yes Not specified
2 Tolvaptan 30–60 Oral Yes
Abbreviations: R, randomized; DB, double-blind; OL, open-label; PC, placebo-controlled; MC, multicenter.
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reduced urine osmolality in patients with cirrhosis to a
lesser extent than in healthy individuals (68). This obser-
vation is in agreement with the idea that impaired water
excretion in cirrhosis is partially due to a vasopressin-
independentmechanism, such as reduceddistal delivery of
filtrate. However, subsequent studies showed favorable
effects of lixivaptan, satavaptan, and tolvaptan on fluid
balance in cirrhosis (69–72). In a recent study, 1200 pa-
tients were included in 3 randomized double-blind trials
comparing satavaptan (5–10 mg/d) with placebo in un-
complicated or difficult-to-treat ascites, with or without
concomitantdiuretic treatment (73). Satavaptanappeared
to confer a slight advantage in delaying ascites formation
and increased serum [Na] in patients with hyponatremia
more effectively than placebo. In patients receiving sata-
vaptan and diuretics, an increasedmortalitywas observed
compared toplacebo, and this caused an early termination
of the study. Specific causes for this finding were not iden-
tified, and the authors reported that most deaths were
associated with complications of cirrhosis.
One trial specifically investigated the effects of vaptans
in cirrhotic patients with hyponatremia. Patients (n 
110) were treated with satavaptan (5–25 mg/d for 14 d)
togetherwith spironolactone (100mg/d) (74). Satavaptan
treatment confirmed the favorable effect in controlling
ascites and caused a significantly greater increase in serum
[Na] than placebo at all the doses that were used. This
findingwas confirmed by a subanalysis of the SALT-1 and
SALT-2 trials, which showed that in the subgroup of cir-
rhotic patients with hyponatremia treatedwith tolvaptan,
the increase in serum [Na] was significantly greater than
in patients treated with placebo, whereas adverse event
rates and deaths were similar in both groups (75).
Vaptans: From Clinical Trials to Clinical
Grounds
Currently, in the United States and Europe there are two
vasopressin receptor antagonists available on the market,
conivaptan (injection formulation) and tolvaptan (oral
tablet). Conivaptan was approved by the US Food and
Drug Administration (FDA) on December 29, 2005, and
is marketed in the United States with the indication of
“treatment of euvolemic and hypervolemic hyponatremia
in hospitalized patients”. Tolvaptan was approved by the
FDA on May 29, 2009, and is marketed in the United
States with the indication of “treatment of clinically sig-
nificant hypervolemic and euvolemic hyponatremia”,
thus including patients with heart failure, cirrhosis, and
SIAD. In Europe, tolvaptan was approved by the Euro-
peanMedicinesAgency (EMA)onAugust 9, 2009, but the
indication was restricted to the “treatment of adult pa-
tients with hyponatremia secondary to SIADH”. Tolvap-
tan treatment should be initiated in a hospital setting but
canbe continued after discharge once the optimal dose has
been established. The availability of an oral formulation
undoubtedly represented an important achievement for
the management of hyponatremia. As mentioned earlier,
it has to be remembered that vaptans are not to be used in
hypovolemic hyponatremia; therefore, a thorough clinical
and diagnostic evaluation should always precede the use
of these drugs.Data summarizing themainpractical issues
regarding the use of conivaptan or tolvaptan are reported
in Table 4.
In clinical practice, whereas hypertonic saline remains
the mainstay of treatment in hypervolemic or euvolemic
patients with severe hyponatremia-related symptoms,
such as respiratory distress, seizures, and coma, vaptan
treatment can be considered a valuable option in: 1) hy-
ponatremic patients with moderate symptoms (eg, confu-
sion, disorientation, nausea, unsteady gait), as an alter-
native to hypertonic saline infusion; or 2) patients with
mild symptoms (eg, mild neurocognitive alterations, de-
pression)or asymptomatic, if fluid restriction fails or is not
tolerated (76) (Figure 3). Vaptans can be reasonably taken
into consideration as the first-choice treatment instead of
fluid restrictionwhen the kidneys are not excreting solute-
free water, according to the urine/serum electrolyte ratio
Table 4. Summary of the Main Practical Issues
Regarding the Use of Marketed Vaptans
Conivaptan Tolvaptan
Dosage forms
and
strengths
Intravenous injection
solution:
conivaptan
hydrochloride 20
mg/100 ml
premixed in 5%
dextrose
Tablets, 15 and 30
mg
Starting dose Loading dose: 20 mg
administered over
30 min, followed
by continuous
infusion, 20 mg/d
15 mg once daily
Dose titration After initial day of
treatment, dosage
can be increased
to 40 mg/d
(continuous
infusion)
Dosage may be
increased at
intervals 24 h to
30 mg once daily,
and to a maximum
of 60 mg once
daily
Treatment
schedule
Up to 4 d Variable
Serum Na
monitoring
At least every 6 h
during initiation
and dose titration
At least every 6 h
during initiation
and dose titration
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(77), or as a trial to treat symptoms likely due to hypo-
natremia. A prompt use of these drugs can be also rec-
ommended in surgical and neoplastic patients with eu-
volemic or hypervolemic hyponatremia, in order to
obtain a rapid correction and avoid any treatment de-
lay. Noticeably, pretreatment hyponatremia has been
independently associated with a shorter survival time in
neoplastic patients (78), and failure to normalize serum
[Na] has been identified as a negative prognostic fac-
tor in these patients (79). Hyponatremia appears to be
a particularly important issue in those patients who
have to start chemotherapy with drugs that can worsen
hyponatremia, such as platinum-based antineoplastic
agents, cyclophosphamide, vincristine, vinblastine,
melphalan (80), ifosfamide (81), or etoposide (82). It is
worth mentioning that mozavaptan was specifically ap-
proved in 2006 in Japan for the treatment of patients
with paraneoplastic SIAD, although it is neither ap-
proved nor under development in other countries (49).
Critical care patients represent another category of pa-
tients who may effectively benefit from vaptan treatment.
In fact, hyponatremia is a common problem in patients in
intensive care units (prevalence, 30–40%), where it is fre-
quently caused by SIAD and is associated with increased
duration of hospital stay and increased morbidity and
mortality (83). In these patients, vaptan treatment can be
used to correct hyponatremia, which is associated with
many disease states seen in critically ill patients that are
direct causes of SIAD, including serious infections, pneu-
monia or other lung injuries, and pain. The iv agent
conivaptan may be used in patients (in the United States)
who cannot tolerate oral medications.
The general rules that should be strictly followed in the
correction of hyponatremia with active therapies apply
also to patients treated with vaptans. Therefore, serum
[Na] should be monitored frequently (every 4–6 h) to
prevent overly rapid correction of hyponatremia and re-
duce the risk of osmotic demyelination syndrome. Active
therapy should be stopped if the rate of correction exceeds
12 mmol/L within 24 h or 18 mmol/L within 48 h. These
limits should be reduced to 8 mmol/L within 12 h and 12
mmol/L within 48 h in patients with risk factors for de-
veloping central pontine myelinosis (eg, malnutrition, al-
coholism, very low serum [Na], and hypokalemia) (84).
The risks associated with overly rapid correction have
been brilliantly highlighted by Thomas Berl in his article
appropriately titled “Treating hyponatremia: damned if
we do and damned if we don’t” (85). Marketed vaptans
have a 12-h half-life, and daily or continuous adminis-
tration is required to maintain activity. Therefore, the in-
crease in serum [Na] can be limited by stopping the drug
or reducing the dose; when necessary, hypotonic fluid
should be infused to counteract an excessive serum [Na]
increase (13). Although the safety data regarding vaptans
are rather reassuring, some variability in themagnitude of
the responsehasbeenobserved, and inpatientswith serum
[Na] 120 mmol/L greater responses have been docu-
mented, thus suggesting the possibility to use lower doses
compared to those that have been officially approved (Ta-
ble 4). In one study reporting data on patients with SIAD
Hypotonic euvolemic or hypervolemic    
hyponatremia*
Moderate symptoms
(eg, nausea, confusion, 
unsteady gait, disorientation)
Mild symptoms or 
asymptomatic
(eg, mild neurocognitive 
symptoms, depression)
Severe symptoms
(eg, seizures, respiratory 
distress, coma)
• Hypertonic saline • Fluid restriction
Hypertonic saline
 
• Vaptan
 
• If fluid restriction fails 
or is not tolerated 
consider vaptan 
treatment
• Consider vaptan 
treatment as a first 
choice in particular 
situations**
* Other treatment options, including loop diuretics, demeclocycline, urea, lithium, and removal of drugs that are known to cause
hyponatremia, may be considered on a case-by-case basis. Specific treatment of the underlying disease should be started, when possible.
** For instance in hyponatremic patients before surgery or chemotherapy, in patients who are not expected to excrete solute free water, as a
trial to treat symptoms likely related to hyponatremia.
Figure 3. Treatment algorithm for the correction of hypotonic euvolemic or hypervolemic hyponatremia. For specific approvals and indications in
the United States and in Europe see the text.
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treated with iv conivaptan, for instance, lower serum
[Na] was associated with a greater increase 24 h after
initiation of therapy (86). In addition, baseline blood urea
nitrogen, glomerular filtration rate, and creatinine clear-
ance also showed a significant correlation with the abso-
lute increase in serum [Na] at 24 h, and low blood urea
nitrogen and hyperfiltration were predictors of a greater
response.With regard to safety, recentlyboth theFDAand
the EMA have reinforced recommendations about fluid
and electrolytemonitoring in patients treatedwith tolvap-
tan (FDA and EMA) or conivaptan (FDA), together with
warnings on concomitant use of other treatments for hy-
ponatremia, in order to avoid overly rapid and/or exces-
sive corrections. These recommendations followed the ac-
knowledgment of the occurrence of osmotic
demyelination syndrome in association with tolvaptan
treatment by the FDA. However, a causal relationship to
drug exposure has not been clearly established, and the
neurological sequelae might have been caused by im-
proper treatment strategies.
Another practical issue to be considered is the interac-
tion between vaptans and other drugs. Vaptans are me-
tabolized by cytochrome CYP3A4, and therefore caution
shouldbe exercised in case of coadministrationofCYP3A4
inhibitors (eg, ketoconazole, macrolide antibiotics, dilti-
azem) or inducers (eg, rifampicin, barbiturates), which
increase or reduce serum concentrations of vaptans,
respectively (87). Grapefruit is a potent inhibitor of
CYP3A4, and it has been demonstrated that grapefruit
juice increases the bioavailability of tolvaptan (meanmax-
imal concentration: 1.86-fold increase) (88). Thus, pa-
tients taking these drugs should avoid ingesting grapefruit
or grapefruit juice. Tolvaptan treatment did not have any
effect on serum concentrations of other CYP3A4 sub-
strates, such as warfarin or amiodarone (89). Serum
digoxin concentrations have been found to be increased
(mean maximal concentration: 1.27-fold increase) during
coadministration of multiple (16 d) once daily 60-mg
doses of tolvaptan (90). Patients receiving digoxin should
therefore be evaluated for excessive digoxin effects when
treated with vaptans.
The duration of treatmentwith tolvaptan,which is cur-
rently the only V2 receptor antagonist available also for
chronic use, may vary based on several issues, including
the etiology of hyponatremia, the chronicity of the under-
lying disease, the response to the drug, its tolerability, and
the coadministration of other drugs with lowering effects
on serum [Na]. In patients with SIAD, for instance, the
underlying etiologymay predict the duration of tolvaptan
requirement. In fact, inpatientswithparaneoplastic, drug-
induced (without discontinuation of the offending drug),
or idiopathic SIAD, the likely duration of this condition is
indefinite. In other situations, SIAD may be a temporary
condition, limited to a few weeks (eg, after subarachnoid
hemorrhage, stroke) or even a few days (eg, in postoper-
ative hyponatremia, pneumonia), and a temporary treat-
ment with tolvaptan may be foreseen.
An important issue about the use of drugs, particularly
newlymarketed drugs, is the cost/effectiveness analysis. A
retrospective cohort analysis showed that the length of
stay (LOS) in the hospital was 2 days longer for patients
admitted with hyponatremia, and admittance to the in-
tensive care unit was 10% higher for patients with mod-
erate-to-severe hyponatremia compared with normona-
tremic patients (91). Another large retrospective analysis
reported that patients with hyponatremia had an 18%
increase in total healthcare costs compared to patients
without hyponatremia (3). An analysis of the impact of
hyponatremia on 1-year direct medical costs using longi-
tudinal data from a largemanaged care claims database in
the United States (National Managed Care Benchmark
Database) showed a 45.7% increase in hyponatremic vs
normonatremic patients (92).Another study reported that
in a high-risk population of patients hospitalized forCHF,
the hospitalization costs attributed to hyponatremia were
increased up to more than $1000 in patients with severe
hyponatremia (93).Thepost hoc analysis of theLOS in the
hospital in patientswith hyponatremia secondary to SIAD
enrolled in the SALT-1 and SALT-2 trials revealed a trend
toward a reduced LOS in the tolvaptan group (mean,
4.98d) compared to the placebo group (mean,6.19d) (51).
The post hoc analysis of the EVEREST trial showed that
patients with hyponatremia treated with tolvaptan had a
15% decreased LOS in comparison with patients given
placebo (94). Admittedly, the crucial question remains
whether treatment with vaptans may be associated with
hospital cost savings.To this purpose, twoeconomicmod-
els based on the results of the SALT-1/SALT-2 and EVER-
EST trials have been constructed. The LOS reduction re-
vealed by the post hoc analyses of these trials was applied
to the associated costs and resource usage of a US study
population from the Nationwide Inpatient Sample data-
base. These models predicted an estimated cost offset as-
sociated with tolvaptan treatment of $694 per admission
and $15million/year for patients with SIAD, based on the
SALT-1/SALT-2 trials (95), and of $265 per admission
and $21 million/year for hyponatremic patients with
CHF, based on the EVEREST trial (96).
Vaptans: Future Perspectives
Vaptans appeared to hold their initial promises and have
been generally recognized in the last few years as an ad-
8 Peri Vaptans in Endocrinology J Clin Endocrinol Metab, April 2013, 98(4):0000–0000
ditional effective and safe tool for the correction of euv-
olemic or hypervolemic forms of hyponatremia. It may be
true, as Peter Gross, Andrea Wagner, and Guy Decaux
titled their review article on vaptans in 2011, that “vap-
tans are not the mainstay of treatment in hyponatremia:
perhaps not yet” (97). However, the issues raised by these
authors about the exact indications for vaptans, the effects
on LOS in the hospital and on mortality, the cost/effec-
tiveness analysis, and the optimal regimen have been at
least partially solved or are being thoroughly investigated.
Nevertheless, more comparative research of vaptans vs
other therapies and analyses of patients treated with these
drugs on clinical grounds are needed to better determine
the benefits on patient outcome and more accurately as-
sess the exact role and the valueof vaptans in the treatment
of hyponatremia. With regard to this point, real-life cost/
benefit analyses will be also needed.
Although it is beyond the aim of this review, which is
addressed to endocrinologists, it is worth mentioning fi-
nally that another possible area of application of vaptans
maybepolycystic kidneydisease (PKD),which remains an
unsolved medical problem. OPC-31260 and tolvaptan
have been effective in reducing cAMP levels in kidney ep-
ithelial cells and cystogenesis in PKD models (98–100).
Several clinical studies investigating the effects of tolvap-
tan in autosomal dominant PKD (ADPKD) have been per-
formed under the Tolvaptan Efficacy and Safety in Man-
agement of ADPKD and Outcomes (TEMPO) program.
Very recently, the results of a phase 3,multicenter, double-
blind, placebo-controlled, 3-year trial within the TEMPO
program were published (101). Tolvaptan (average dose,
95 mg/d) significantly slowed the increase in total kidney
volume and the decline in kidney function, compared to
placebo. However, a higher discontinuation rate was ob-
served in patients receiving tolvaptan compared to the pla-
cebo group (23 vs 13.8%, respectively), mostly due to the
effect on aquaresis and to elevation of liver-enzyme levels,
which returned to baseline after discontinuation of the
drug. Therefore, at this time the potential benefit of
tolvaptan in patients with ADPKD needs to be further
weighted against risks.
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